George Kemble Acquires Shares of Sagimet Biosciences

George Kemble recently purchased 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) on June 12, 2026. The shares were acquired as part of an insider transaction, with the stock trading at $6.48 at the time of the purchase.

Other Institutional Activity in Sagimet Biosciences

Vanguard Capital Management LLC significantly boosted its position in Sagimet Biosciences by adding 1,098,919 shares, bringing its total to 1,098,919 shares valued at approximately $5.74 million. Marshall Wace, LLP also increased its holdings by 185,807 shares, reaching a total of 966,253 shares worth about $5.04 million. Meanwhile, Affinity Asset Advisors, LLC reduced its stake by 280,225 shares, ending with 868,020 shares valued at $4.54 million.

Sagimet Biosciences Stock Snapshot

Shares of Sagimet Biosciences (NasdaqGM: SGMT) traded at $6.48. The company, with a market cap of approximately $399.5 million, operates in the biotechnology sector. It has no meaningful P/E ratio due to its negative earnings. The stock's 52-week range is between $4.50 and $11.41, with a 50-day moving average of $6.82 and a 200-day moving average of $6.56. Sagimet maintains a strong balance sheet with a current ratio of 20.34 and a quick ratio of 19.74.

Recent Earnings

Sagimet Biosciences is expected to report its next earnings on August 12, 2026. The company has been working on developing novel therapeutics, but it currently has negative earnings per share (EPS) of -$1.35 and a return on equity (ROE) of -36.04%.

Insider Buying and Selling at Sagimet Biosciences Inc.

On June 12, 2026, several insiders, including Beth Seidenberg, Paul Hoelscher, Elizabeth Grammer, Anne Phillips, and Jennifer Jarrett, each purchased 39,567 shares of Sagimet Biosciences. These transactions were not conducted under a Rule 10b5-1 plan.

Analysts Set New Price Targets

On May 19, 2026, Citizens maintained a 'buy' rating for Sagimet Biosciences with a price target of $12.00. Canaccord Genuity, on May 4, 2026, also maintained a 'buy' rating with a higher target of $49.00. Guggenheim, on April 29, 2026, reiterated its 'buy' rating with a target of $25.00. The consensus among analysts is a 'buy' rating, with a mean price target of $26.20 based on 10 analyst opinions.

About Sagimet Biosciences

Sagimet Biosciences Inc., based in San Mateo, California, is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors to treat diseases related to metabolic and fibrotic pathways. Their lead candidate, Denifanstat, is an oral pill designed for conditions like metabolic dysfunction-associated steatohepatitis, acne, and certain cancers. The company, led by CEO David A. Happel, has 16 employees.

Bottom Line

George Kemble's recent purchase of Sagimet Biosciences shares highlights ongoing interest in the company's potential. Investors closely watch insider trading for signals, though it's important to remember that 13F filings and insider transactions reflect past actions and may not indicate current positions. With a focus on novel therapeutics, Sagimet Biosciences remains a company of interest, especially with multiple 'buy' ratings from analysts.